March 25th 2025
Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.
Ready, Set, Cabenuva: Implementing Cabotegravir/Rilpivirine
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Read More
HIV Prevention Plan in Namibia Shows High Prevalence of Risk Factors
December 2nd 2021Study authors from the CDC found that girls in the sub-Saharan country of Namibia are at increased risk for HIV acquisition and also experience risk factors that make them eligible for HIV infection prevention programs.
Read More
Provider Stigma Can Prevent Injection Drug Users from Receiving HIV PrEP
November 13th 2021Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.
Watch